Premium
Theranostic Bioabsorbable Bone Fixation Plate with Drug‐Layered Double Hydroxide Nanohybrids
Author(s) -
Kim Myung Hun,
Hur Woojune,
Choi Goeun,
Min Hye Sook,
Choi Tae Hyun,
Choy Young Bin,
Choy JinHo
Publication year - 2016
Publication title -
advanced healthcare materials
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.288
H-Index - 90
eISSN - 2192-2659
pISSN - 2192-2640
DOI - 10.1002/adhm.201600761
Subject(s) - radiodensity , materials science , biocompatible material , layered double hydroxides , hydroxide , biomedical engineering , drug , chemistry , medicine , surgery , pharmacology , organic chemistry , radiography
A bioabsorbable polymeric bone plate enabled with both diagnostic and therapeutic functionalities (radiopacity and sustained drug release, respectively) is proposed. To this end, a drug–inorganic nanohybrid (RS‐LDH) is examined as a theranostic agent by intercalating an anti‐resorptive bone remodeling drug, risedronate (RS) into a layered double hydroxide (LDH) via an ion‐exchange reaction. The RS‐LDH is prepared as a sheet with a biodegradable polymer, poly(lactic‐ co ‐glycolic acid), and is then attached onto the clinically approved bioabsorbable bone plate to produce the theranostic plate. Because of the presence of the metals in the LDH, the theranostic plate results in discernible in vivo X‐ray images for up to four weeks after implantation. Concurrently, bone regeneration is also significantly improved compared with the other control groups, likely because of this material's sustained drug‐release property. The theranostic plate is also largely biocompatible, similar to the plate already approved for clinical use. It is concluded that the combination of a biodegradable bone plate with RS‐LDH nanohybrids can constitute a promising system with theranostic ability in both X‐ray diagnosis and expedited bone repair.